A technician prepares to refuel a Delta Airlines aircraft at the Austin-Bergrstrom International Airport on April 10, 2026 in Austin, Texas. Brandon Bell | Getty Images U.S. airlines spent 56.4% more on jet fuel in March, the month after the U.S.-Israel strikes on Iran began, than they did in February, U.S. government data released Wednesday show. U.S. carriers spent $5.06 billion on fuel in March...
A technician prepares to refuel a Delta Airlines aircraft at the Austin-Bergrstrom International Airport on April 10, 2026 in Austin, Texas. Brandon Bell | Getty Images U.S. airlines spent 56.4% more on jet fuel in March, the month after the U.S.-Israel strikes on Iran began, than they did in February, U.S. government data released Wednesday show. U.S. carriers spent $5.06 billion on fuel in March, up from $3.23 billion in February. It was 30% more than what they paid in March 2025, according to the Department of Transportation . Airlines have lowered or scrapped their 2026 forecasts altogether because of the spike in fuel, their biggest expense after labor. Some carriers have scaled back growth plans to cut costs and avoid having too much expensive capacity in the markets. watch now VIDEO 3:10 03:10 Here's how jet fuel crisis in Europe threatens summer travel plans Digital Original The spike in jet fuel was even sharper and topped $4 a gallon in some markets in April as the war continued and the Strait of Hormuz was effectively closed. Spirit Airlines collapsed over the weekend, and the carrier said the surge in jet fuel costs foiled its plans to emerge from bankruptcy mid-year. Other major carriers told Wall Street as they reported earnings last month that they expect customers to cover the higher jet fuel costs by early 2027, if not the end of this year. So far, booking trends show consumers are still traveling , In March, travel-agency ticket sales rose 12% from a year ago to $10.4 billion, with the number of domestic trips up 5% and international up 1%, according to the Airlines Reporting Corp. Read more CNBC airline news Spirit starts monthslong process of dismantling airline after biggest collapse in a generation 'Godspeed my friend': Inside the final hours of Spirit Airlines United Airlines CEO confirms he approached American Airlines about merger U.S. airlines are hiking fares — and travelers keep booking Choose CNBC as your preferred source on Google and n...
Earnings Call Insights: Jackson Financial (JXN) Q1 2026 Management View CEO Laura Prieskorn said “2026 is off to a strong start” and highlighted “total adjusted capital of $5.5 billion” and a “$288 million” distribution from the operating company to the holding company, alongside “$257 million” returned to common shareholders. CEO Prieskorn tied earnings momentum to business mix, saying “growth of...
Earnings Call Insights: Jackson Financial (JXN) Q1 2026 Management View CEO Laura Prieskorn said “2026 is off to a strong start” and highlighted “total adjusted capital of $5.5 billion” and a “$288 million” distribution from the operating company to the holding company, alongside “$257 million” returned to common shareholders. CEO Prieskorn tied earnings momentum to business mix, saying “growth of spread-based earnings more than offset the impact of market volatility on fee income,” and added, “We expect continued momentum here driven by our spread-based business and the benefits of our expanding product lineup.” CEO Prieskorn highlighted sales and positioning in RILA and spread-based products: “retail annuity sales increased 31% from a year ago,” RILA sales “have now exceeded $2 billion in quarterly sales,” and Jackson has become “the industry's third largest RILA provider with more than $21 billion in RILA assets.” CEO Prieskorn emphasized fixed and FIA momentum: “fixed annuity and FIA sales reached $756 million,” and said the recently launched Jackson Income Assurance “has been positively received, and we expect FIA sales momentum to continue.” CFO Don Cummings reported “pretax adjusted operating earnings of $430 million or $503 million, excluding notable items,” and said sequential ex-notables earnings were “modestly lower than the fourth quarter of 2025” due to “approximately $30 million of headwinds in fee income.” Outlook CEO Prieskorn said, “we've started the year off strong and are on track to achieve our 2026 financial targets,” including “our 2026 free capital generation target of $1.2 billion, along with our capital return to common shareholders in the range of $900 million to $1.1 billion.” CFO Cummings reiterated the framework for the target: “For full year 2026, we continue to expect to generate at least $1.2 billion in free capital, assuming equity markets deliver a 5% return and interest rates move in line with the year-end forward curve.” Compared ...
Earnings Call Insights: Kimball Electronics (KE) Q3 FY 2026 Management View “Results for the third quarter were in line with expectations,” and “Sales increased sequentially compared to Q2 driven by strong growth in our Medical vertical market,” said CEO Richard Phillips, adding that “Margins remain solid and cash from operations was positive for the ninth consecutive quarter.” CEO Richard Phillip...
Earnings Call Insights: Kimball Electronics (KE) Q3 FY 2026 Management View “Results for the third quarter were in line with expectations,” and “Sales increased sequentially compared to Q2 driven by strong growth in our Medical vertical market,” said CEO Richard Phillips, adding that “Margins remain solid and cash from operations was positive for the ninth consecutive quarter.” CEO Richard Phillips said the company is “affirming our guidance for fiscal 2026 with adjusted operating margin estimated to be at the high end of the range,” while positioning Medical CMO as central to strategy: “we are making deliberate investments in our capabilities, operating capacity and commercial focus,” and “When volumes ramp, we expect it to become a meaningful driver of both top line growth and margin expansion.” On growth and mix, CEO Richard Phillips reported: “Net sales were $353 million, an increase of 3.4% compared to the prior quarter, with Medical up 10%,” and highlighted the prior-year comparison distortion from “a nonrecurring sale of consigned inventory, totaling $24 million in the medical market.” CEO Richard Phillips framed Medical scale as a milestone: “Sales in the third quarter were $106 million or 30% of the total company,” and described the Indianapolis site’s positioning: “With capabilities in precision-injected molded plastics, complete device assembly and cold chain management, we are uniquely positioned to produce medical disposables, surgical instruments and selected drug delivery devices such as auto-injectors.” CFO Jana Croom said profitability and cash generation reflected mix and investments: “The gross margin rate in the third quarter was 7.9%,” and “Adjusted operating income in Q3 was $14.8 million or 4.2% of net sales,” while noting ongoing spend: “expenses will be higher in FY '26 as we make strategic investments in business transformation, IT solutions that drive innovation and efficiency, and business development for the future.” Outlook CFO Jana Cro...
KKR & Co. ( KKR ) declares $0.195/share quarterly dividend, 5.4% increase from prior dividend of $0.185. Forward yield 0.78% Payable May 29; for shareholders of record May 15; ex-div May 15. See KKR Dividend Scorecard, Yield Chart, & Dividend Growth. More on KKR & Co. KKR & Co. Inc. (KKR) Q1 2026 Earnings Call Transcript KKR's Durable Growth Story Is Underappreciated KKR & Co. Inc. 2026 Q1 - Resul...
KKR & Co. ( KKR ) declares $0.195/share quarterly dividend, 5.4% increase from prior dividend of $0.185. Forward yield 0.78% Payable May 29; for shareholders of record May 15; ex-div May 15. See KKR Dividend Scorecard, Yield Chart, & Dividend Growth. More on KKR & Co. KKR & Co. Inc. (KKR) Q1 2026 Earnings Call Transcript KKR's Durable Growth Story Is Underappreciated KKR & Co. Inc. 2026 Q1 - Results - Earnings Call Presentation 'Credit card spending is through the roof' - NEC's Hassett KKR signals 2026 ANI more likely below $7 per share while targeting $100B-plus AUM with Arctos
CharlieAJA/iStock via Getty Images Viatris ( VTRS ) is scheduled to report first-quarter earnings results on Thursday, May 7, before the market opens. Investors and analysts will be watching for signs of stabilization across its generics and branded drugs portfolio amid continued pricing pressure in the pharmaceutical sector. Wall Street expects the Pennsylvania-based drugmaker to post earnings of...
CharlieAJA/iStock via Getty Images Viatris ( VTRS ) is scheduled to report first-quarter earnings results on Thursday, May 7, before the market opens. Investors and analysts will be watching for signs of stabilization across its generics and branded drugs portfolio amid continued pricing pressure in the pharmaceutical sector. Wall Street expects the Pennsylvania-based drugmaker to post earnings of $0.50 per share , flat from the year-ago period, on revenue of $3.36B, representing a 3.4% year-over-year increase. Over the past two years, Viatris has beaten EPS estimates 75% of the time and topped revenue expectations in 75% of quarterly reports, suggesting a relatively consistent track record of outperforming consensus forecasts. Analyst sentiment has turned relatively cautious heading into the print. Over the past three months, EPS estimates have seen four downward revisions and no upward revisions , while revenue estimates recorded two upward revisions against one downward revision. In focus will be the company’s progress in reshaping its portfolio, debt reduction efforts, and performance across key legacy brands and complex generics. Updates around biosimilars, new product launches, and margin trends could also influence sentiment. The report comes as Viatris continues navigating a challenging environment marked by generic drug pricing pressure, currency fluctuations, and broader healthcare sector uncertainties. The Xanax maker reported largely unchanged generics revenue in Q4, amid competition for certain products in North America. Its Brands division generated ~8% Y/Y growth driven by strength in Greater China and Emerging Markets. Viatris managed to improve its adjusted gross margin to 56.8% in 2025 from 56.3% in 2024, while its adjusted EPS slipped in the year . More on Viatris Viatris Inc. (VTRS) Discusses Long-Term Growth Outlook and Portfolio Strategy Across Generics, Established Brands and Innovative Medicines Transcript Viatris Inc. (VTRS) Discusses Long-T...
In this article SHEL SHEL Follow your favorite stocks CREATE FREE ACCOUNT watch now VIDEO 2:59 02:59 This oil stock stands out as traffic in the Strait of Hormuz remains halted Options Action While the broader market grapples with geopolitical instability, Shell plc (SHEL) , along with other large integrated oil companies, have benefited from higher oil prices and should warrant investor attention...
In this article SHEL SHEL Follow your favorite stocks CREATE FREE ACCOUNT watch now VIDEO 2:59 02:59 This oil stock stands out as traffic in the Strait of Hormuz remains halted Options Action While the broader market grapples with geopolitical instability, Shell plc (SHEL) , along with other large integrated oil companies, have benefited from higher oil prices and should warrant investor attention. Despite the dual blockades by both Iran and the US currently roiling the Strait of Hormuz — the most significant energy supply disruption in modern history — Shell's integrated model and massive trading arm are positioned to thrive. Even if ongoing negotiations lead to a de-escalation, the logistical backlog will take quarters to unwind, keeping energy prices structurally supported, to say nothing of the need to replenish strategic petroleum reserves; an important insurance policy as the world has now been painfully reminded. For investors looking to harvest yield from this environment, I'm targeting a moderately bullish income play. The Trade: Short Cash-Secured Put Action: Sell the June 85 Puts Credit Received: Approximately $1.75(~2% of the strike price) Probability of Profit: >70% Standstill Yield: Just over 17% annualized Degree of difficulty: Intermediate The effective closure of the Strait of Hormuz since late February has removed millions of barrels from the daily global supply. While diplomatic efforts are underway, shipping insurance remains at prohibitive levels. This "higher-for-longer" pricing environment for Brent crude directly feeds Shell's Upstream and Integrated Gas margins. Even a "peace pivot" won't immediately refill global inventories, providing a solid floor for the stock. The company just completed its latest $3.5 billion share buyback program as of May 1st. Given the substantial free cash flow (FCF) generated by high realization prices, management is widely expected to announce a fresh buyback tranche during the upcoming earnings call. Coupled wit...
Starmer is determined to see his five-year term through, even if it’s not what the country or the party wants 'Twas the night before the elections, when all through No 10, not a creature was stirring, not even a hen. Mainly because Downing Street had come to the conclusion that letting Keir Starmer loose on the campaign trail was a surefire way to lose votes. Canvassers from all over the country h...
Starmer is determined to see his five-year term through, even if it’s not what the country or the party wants 'Twas the night before the elections, when all through No 10, not a creature was stirring, not even a hen. Mainly because Downing Street had come to the conclusion that letting Keir Starmer loose on the campaign trail was a surefire way to lose votes. Canvassers from all over the country had confirmed what the polls were saying. That the prime minister was kryptonite to Labour’s chances. Mention his name to voters and people would turn their heads away. Some even made the sign of the cross. It was out of sight, out of mind. The less everyone saw of Keir, the more they decided they liked him. The new dialectics. Keir functioned best as an abstract idea, rather than as a living person. Continue reading...
jirkaejc/iStock via Getty Images By Christopher Gannatti, CFA Global Head of Research, and Dovile Silenskyte Director, Digital Assets Research at WisdomTree in Europe Bitcoin and gold are responding to the same forces. The ratio tells you which one the market is favoring right now. Before asking where Bitcoin’s price is going, or where gold’s price is going, ask something more useful: What should ...
jirkaejc/iStock via Getty Images By Christopher Gannatti, CFA Global Head of Research, and Dovile Silenskyte Director, Digital Assets Research at WisdomTree in Europe Bitcoin and gold are responding to the same forces. The ratio tells you which one the market is favoring right now. Before asking where Bitcoin’s price is going, or where gold’s price is going, ask something more useful: What should the relationship between these two assets look like, given everything happening in the world right now? And then ask: Is that actually what we're seeing? These questions, deceptively simple, are the foundation of a model we have built. It’s called the Bitcoin in Gold model, or BiG for short. It doesn't predict a Bitcoin price. It doesn’t predict a Bitcoin price or a gold price. What it does is considerably more interesting, and understanding how it works may change the way you think about both assets. Why a Ratio? The idea of comparing two assets as a ratio, rather than tracking each one individually, isn’t new. Investors have followed the gold-to-silver ratio for decades, and it specifically measures how many ounces of silver it takes to buy one ounce of gold. Shifts in that ratio have historically told investors something meaningful about relative demand for each metal. 1 When the ratio gets very high, silver looks historically cheap relative to gold. When it compresses, the opposite is true. The ratio doesn’t tell you that gold is definitely going up or silver is definitely going down; it tells you something about the relationship between them, which can be every bit as actionable. Bitcoin and gold, it turns out, are well-suited to this kind of comparative analysis, for a specific reason: They respond to many of the same underlying forces, just with different intensities. Both are what you might call monetary assets, which is to say they’re not claims on a company’s earnings; they don’t pay dividends, and much of their perceived value comes from their role as stores of v...
Despite Health Secretary Robert F. Kennedy's pledge to provide "radical transparency," the agencies under his control continue to suppress scientific research that conflicts with his anti-vaccine agenda. On Tuesday, The New York Times reported confirmation from the Department of Health and Human Services that the Food and Drug Administration had blocked the publication of studies showing the safet...
Despite Health Secretary Robert F. Kennedy's pledge to provide "radical transparency," the agencies under his control continue to suppress scientific research that conflicts with his anti-vaccine agenda. On Tuesday, The New York Times reported confirmation from the Department of Health and Human Services that the Food and Drug Administration had blocked the publication of studies showing the safety and efficacy of vaccines against COVID-19 and shingles . The revelation follows a report from The Washington Post last month that the Centers for Disease Control and Prevention scrapped a scientifically vetted study previously scheduled for publication that found COVID-19 vaccines sharply cut the risk of emergency care and hospitalization among healthy adults. The study was ultimately rejected by Kennedy's acting CDC director, who claimed to have concerns about the study's methodology. Similarly at the FDA, two studies on COVID-19 vaccines by agency scientists were accepted for publication at medical journals, according to the Times. But unnamed FDA officials directed the agency scientists to withdraw the studies. While a preliminary abstract of one of the studies presented at a conference last fall remains online, the Times obtained a copy of the full manuscript, the conclusion of which reads, "Given the available evidence, FDA continues to conclude the benefits of vaccination outweigh the risks." Read full article Comments
Getty Images BigBear.ai Holdings, Inc. ( BBAI ) just reported its Q1 numbers to a lackluster reception. I thought I’d go through the numbers in more depth and give some comments on what the company needs to do to entice me in the future, because right now, I am not convinced. Numbers In Depth Revenues came in essentially flat at $34.4m, which beat estimates by $840k (-1% y/y). Army programs were t...
Getty Images BigBear.ai Holdings, Inc. ( BBAI ) just reported its Q1 numbers to a lackluster reception. I thought I’d go through the numbers in more depth and give some comments on what the company needs to do to entice me in the future, because right now, I am not convinced. Numbers In Depth Revenues came in essentially flat at $34.4m, which beat estimates by $840k (-1% y/y). Army programs were the main culprit for such a lackluster performance, which offset Ask Sage revenues tremendously. The company doesn’t disclose any revenue breakdown, so we cannot look into that any further. Another key performance metric that is essential to look at is the company’s backlog and how it progressed over the last year, as well as sequentially. Backlog is up 14% sequentially to $281.9m, which was primarily driven by a single large contract, to the tune of $53m. The most recent backlog number is increasing sequentially; it is still down around 27% y/y. The last time the company even reported backlog numbers was back in Q3 ’25, when they were at $376m. I don’t like it when management is not transparent about some of the critical points of the results, but I understand why. It went down considerably, and it may be coming back up, unless it was just a fluke. If the company doesn’t report next quarter, it’s a pretty good telltale sign that the backlog declined once again. Going over BBAI’s efficiency and profitability, we can see that the management is highlighting the increase in the overall gross margins of a whopping 1,278 basis points. Gross margins went from 21.3% to 34%. That is a very good improvement, which is due to increased volume from Ask Sage’s high-margin products, like its GenAI platform and other related products. It’s a bit odd that the most progress the company saw in operations was due to an acquisition of Ask Sage back in November-December of last year, 2025. I suppose if internal operations aren’t as impressive, then make them more impressive through inorganic mea...